Pku Healthcare Corp.Ltd(000788) ( Pku Healthcare Corp.Ltd(000788) ), which was hyped by the funds of the “quantitative headquarters” business department, resulting in abnormal fluctuations in stock trading, issued an announcement on the 13th, leaving aside the drug cooperation plan relationship with yanyeyi pharmaceutical company of Japan.
Pku Healthcare Corp.Ltd(000788) said that the company was concerned about the recent media reports on the progress of oral drugs for the treatment of covid-19 virus developed by yanyeyi pharmaceutical company in Japan. At present, the company has no plan to cooperate with foreign manufacturers
Since March, Pku Healthcare Corp.Ltd(000788) has closed three trading limits in a row. From the perspective of disassembly, Pku Healthcare Corp.Ltd(000788) this round of sharp rise is inseparable from Japan yanye pharmaceutical company in terms of news.
At the end of February, Japan yanyeyi pharmaceutical company announced that it had applied to the Ministry of health, labor and welfare of Japan for the production and sales license of covid-19 virus oral medicine. If recognized, it will be the first Japanese made covid-19 oral drug approved for marketing.
Behind this Japanese pharmaceutical enterprise, the investor comes from Ping An Insurance (Group) Company Of China Ltd(601318) department. Pku Healthcare Corp.Ltd(000788) as a listing platform of Ping An health, it has a nationwide sales network and a perfect API production line. Therefore, it also encountered the crazy hunting of secondary market funds.
however, in the announcement tonight, Pku Healthcare Corp.Ltd(000788) also made it clear that the equity transfer and asset delivery of the original actual controllers of the company, Peking University Founder Group Co., Ltd. and Peking University Medical Industry Group Co., Ltd., have not been completed due to the reorganization of Founder group, Pku Healthcare Corp.Ltd(000788) 2019 and 2020 annual reports were issued with qualified audit reports by Tianjian certified public accountants for the risk of related deposits, related guarantees and overdue accounts receivable of related transactions. The above-mentioned risk matters are still uncertain.
This is equivalent to that Pku Healthcare Corp.Ltd(000788) has been written off in time from drug cooperation plan to equity connection.
From a broader perspective, Pku Healthcare Corp.Ltd(000788) is not the only company to be supported by funds because of the optimistic expectation of yanye pharmaceutical company in Japan.
Comparatively speaking, Changjiangrunfa Health Industry Co.Ltd(002435) has a more active share price performance. In early March this year, investors asked whether Changjiangrunfa Health Industry Co.Ltd(002435) has a cooperative relationship with Changao Pharmaceutical Technology Group under yanyeyi Pharmaceutical Co., Ltd. Changjiangrunfa Health Industry Co.Ltd(002435) said that Hailing pharmaceutical, a subsidiary of the company, and Changao group reached cooperation on “Lulit” luliconazole cream products in 2020.
Recently, Apeloa Pharmaceutical Co.Ltd(000739) , whose share price performance has become active, has also caught the “express” of yanye pharmaceutical company in Japan. On March 9, an investor asked that the company is a supplier of raw materials and intermediates of yanyeyi pharmaceutical in Japan. Could you tell me whether the company’s products are used in covid-19 oral drugs related to yanyeyi. Pro pharmaceutical responded that the company has a strict confidentiality agreement with cdmo customers and will not disclose any customer and project related information.
Pku Healthcare Corp.Ltd(000788) leaving aside the cooperative drug plan with yanye Yi, the most obvious impact from the secondary market is undoubtedly the funds bought in the continuous sharp rise of the company’s share price.
On March 11, Pku Healthcare Corp.Ltd(000788) published the data of the dragon and tiger list, which showed that the net purchase of funds was 706696 million yuan. From the perspective of disassembly, Huaxin Securities Shanghai Branch, known as the “quantitative base”, is listed as buying one seat, and China stock market news securities Lhasa, known as the “retail base”, is listed as selling two seats.
The most noteworthy is Huaxin Securities Shanghai Branch. This seat has also recently appeared in the long list of A-share diagnostic companies such as Shanghai Labway Clinical Laboratory Co.Ltd(301060) , Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) and so on, which shows that it is optimistic about the covid-19 antigen detection market. However, with Pku Healthcare Corp.Ltd(000788) tonight’s announcement, whether the influx of funds in recent days can be safe remains to be answered by the stock price performance after the opening of the market next week.
